Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Drug
By Rediff Money Desk, NEWDELHI Dec 01, 2023 14:50
Zydus Lifesciences receives USFDA approval for its generic version of Ivabradine tablets, indicated for the treatment of heart failure. The drug will be manufactured in Ahmedabad, India.
![Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Drug](https://im.rediff.com/money/2012/oct/28drug.jpg)
New Delhi, Dec 1 (PTI) Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Ivabradine tablets indicated for the treatment of heart failure.
The approval by the US Food and Drug Administration (USFDA) is for Ivabradine tablets of strengths 5 mg and 7.5 mg, the company said in a regulatory filing.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India, it added.
Ivabradine is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with certain conditions, the company said.
It is also used in children aged six months and older for the treatment of stable
symptomatic heart failure due to cardiomyopathy, it added.
Zydus said it was one of the first abbreviated new drug application (ANDA) applicants to submit a substantially complete ANDA with a paragraph IV certification for Ivabradine Tablets, 5 mg and 7.5 mg, and therefore, may be eligible for 180 days of shared generic exclusivity for the same.
Ivabradine tablets, 5 mg and 7.5 mg recorded annual sales of USD 136.5 million in the US, the company said, citing IQVIA MAT October 2023 data.
The approval by the US Food and Drug Administration (USFDA) is for Ivabradine tablets of strengths 5 mg and 7.5 mg, the company said in a regulatory filing.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India, it added.
Ivabradine is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with certain conditions, the company said.
It is also used in children aged six months and older for the treatment of stable
symptomatic heart failure due to cardiomyopathy, it added.
Zydus said it was one of the first abbreviated new drug application (ANDA) applicants to submit a substantially complete ANDA with a paragraph IV certification for Ivabradine Tablets, 5 mg and 7.5 mg, and therefore, may be eligible for 180 days of shared generic exclusivity for the same.
Ivabradine tablets, 5 mg and 7.5 mg recorded annual sales of USD 136.5 million in the US, the company said, citing IQVIA MAT October 2023 data.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![Ripley & Co to...](https://im.rediff.com/80-80/money/2024/jan/29port.jpg)
Ripley & Co to Modernize Haldia Berth with Rs...
Ripley & Co and Bothra Shipping Services will invest Rs 600 crore to automate and...
![India To Set Up...](https://im.rediff.com/80-80/money/2020/sep/15business-2.jpg)
India To Set Up Centre For Trade Negotiation...
India's Commerce Ministry plans to establish a centre for negotiation skills to...
![SBI 444-Day Term...](https://im.rediff.com/80-80/money/2017/aug/01bank.jpg)
SBI 444-Day Term Deposit: Up to 7.25% Annual...
State Bank of India launches a 444-day term deposit offering up to 7.25% annual...